XML 83 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2023 $ 140,000 $ 319,963,000 $ (256,176,000) $ 63,927,000 $ 19,287,000 $ 83,214,000
Balance, shares at Dec. 31, 2023 7,067,772          
Initial public offering of Impact BioMedical $ 1,000 1,922,000 1,923,000 304,000 2,227,000
Net loss (14,034,000) (14,034,000) (1,728,000) (15,762,000)
Balance at Sep. 30, 2024 $ 141,000 321,885,000 (270,210,000) 51,816,000 17,863,000 69,679,000
Balance, shares at Sep. 30, 2024 7,067,772          
Balance at Dec. 31, 2024 $ 161,000 323,150,000 (303,072,000) 20,239,000 12,477,000 32,716,000
Balance, shares at Dec. 31, 2024 8,092,518          
Net loss (9,184,000) (9,184,000) (903,000) (10,087,000)
Issuance of common stock, net of expenses - Impact BioMedical, Inc. 1,000 2,082,000 2,083,000 331,000 2,414,000
Issuance of common stock for bonus $ 20,000 850,000 870,000 870,000
Issuance of common stock for bonus, shares 1,000,000            
Stock based payments for professional services rendered for Impact Bio 190,000 190,000 190,000
Stock based payments for professional services rendered for Impact Bio, shares            
Stock based payments 5,000 5,000 5,000
Balance at Sep. 30, 2025 $ 182,000 $ 326,277,000 $ (312,256,000) $ 14,203,000 $ 11,905,000 $ 26,108,000
Balance, shares at Sep. 30, 2025 9,092,518